About SanionaSaniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A and Luc Therapeutics, Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,500 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION.
Founder and CEO: Jørgen Drejer
Founder and CFO: Thomas Feldthus
Founder and CSO: Palle Christophersen
48 articles about Saniona
The first quarter hasn't been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.
Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team
Saniona, a clinical-stage biopharmaceutical company focused on rare diseases, announced that it will refocus its strategy on ion channel research and development and, as a result, further streamline its operations.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartis’s January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake.
1/3/2022Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look.
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).
Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat the Chairman and the CEO, as well as additional members of the Board of Directors and executive management team, have purchased 82,000 shares of the company in the open market for a total value of approximately SEK 861,182.
11/22/2021With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
Saniona achieved orphan drug designation (ODD) from the FDA for Tesomet for the treatment of hypothalamic obesity (HO).
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Saniona announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity.
Saniona today announced that it will present at multiple upcoming virtual investor conferences this fall. Details are as follows: Aktiespararna’s Aktiedagen Stockholm 2021 Date/Time: 11 October 2021, 19.00 CEST / 1:00 p.m. EDT
Saniona today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders’ meeting held on September 16, 2021
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announced the appointment of Wendy Dwyer as Chief Business Officer.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
Saniona announced that it has dosed the first patientin a Phase 1 clinical trial of SAN711,a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors and may be applicable in the treatment of rare neuropathic disorders.
Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology
Saniona today announced it will present preclinical data on SAN711 in a model of facial neuropathic pain at the 7th Congress of the European Academy of Neurology.
The U.S. Food and Drug Administration granted orphan drug designation to Tesomet for the treatment of Prader-Willi syndrome (PWS). This designation qualifies Saniona for certain development benefits, including tax credits, elimination of certain FDA license application fees, and seven years of market exclusivity in the U.S. following approval.
Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE™ database.
Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat it will host a virtual R&D day event on Thursday, May 20, 2021, at 11:00 am EDT / 17:00 CEST.